US equities |
SPCX $166.84 ▲+4.96% NVDA $236.29 ▲+1.00% MU $1,062.91 ▼-1.11% TSLA $376.92 ▲+1.71% MSFT $524.46 ▲+1.34% SNDK $1,705.03 ▼-0.87% INTC $117.34 ▼-1.67% META $742.43 ▲+1.97%
FinancialContent

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

15.26 +0.06 (+0.36%)
Delayed Quote Updated: 12:20 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
News headline image
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks ↗
On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ... 
Via Benzinga
News headline image
Looking Into Dyne Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Peering Into Dyne Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path ↗
JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor concerns over data updates. 
Via Benzinga
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday? ↗
Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated Approval by 2026. 
Via Benzinga
News headline image
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Dyne, Napco, and Franklin and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
DYNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Dyne Therapeutics, Inc. on Behalf of Dyne Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Dyne Therapeutics, Inc. (DYN)
From Kirby McInerney LLP
Via Business Wire
News headline image
DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
DYN Investors Have Opportunity to Join Dyne Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >